期刊
MOLECULAR PHARMACEUTICS
卷 18, 期 11, 页码 4090-4098出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.1c00514
关键词
alginate-based nanogel; injectable hydrogel; drug delivery system; ovarian cancer; peritoneal dissemination; cisplatin
资金
- Japanese Ministry of Education, Science, and Culture [20K08989, 21K09489]
- Ministry of Health, Labour and Welfare [19FB1001]
- Grants-in-Aid for Scientific Research [20K08989, 21K09489] Funding Source: KAKEN
The newly developed alginate-based hybrid system in intraperitoneal chemotherapy shows potential applicability for delivering cisplatin into peritoneally disseminated ovarian cancer tissues, allowing sustained drug release and significant antitumor activity in vivo. It may serve as a novel strategy for treating advanced-stage ovarian cancer with KRAS mutations.
Intraperitoneal chemotherapy demonstrates potential applicability in the treatment of peritoneally disseminated ovarian cancer because the disseminated tumors can directly receive exposure to high concentrations of anticancer drugs. However, a considerable proportion of drugs, particularly micro-molecular and hydrophilic drugs, such as cisplatin (CDDP), are often excreted through glomerular filtration for a short period. To effectively deliver CDDP into peritoneally disseminated ovarian cancer tissues, we developed an alginate (AL)-based hybrid system in which a CDDP-loaded AL nanogel (AL/CDDP-nanogel) was encapsulated in an injectable AL-hydrogel cross-linked with calcium ions. This system enabled the sustained release of CDDP from the AL/CDDP-nanogel/AL-hydrogel hybrid for over a week. Herein, we constructed a peritoneally disseminated ovarian cancer mouse model using ovarian cancer cell lines with KRAS mutations (ID8-KRAS: KRAS(G12V)). The AL/CDDP-anogel/AL-hydrogel hybrid system showed significant antitumor activity in vivo. This therapy may be considered a novel strategy for the treatment of advanced-stage ovarian cancer with KRAS mutations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据